Checked 2026-11-10. Independent clinical review has not been completed. WADAFUK is independent of WADA and does not provide medical advice or an individual anti-doping determination.
Prohibited at all times
2026 S4.3: prohibited at all times. Non-Specified. [1]
S4.3 · 2026 rules apply from 1 January 2026. Any 2027 material below concerns future rules from 1 January 2027; it is not current clearance.
Clinical research
Stamulumab is indexed by NLM as MYO-029. A randomized safety study in 116 adults with several muscular dystrophies reported skin hypersensitivity at higher exposures. Exploratory strength and function endpoints did not improve; the study was not powered to establish efficacy. [2] [3]
- Primary-study abstract reviewed through an author institution; no evidence here establishes a healthy-person benefit or long-term safety.
Check the sources.
These are concise editorial paraphrases of selected sources, not a systematic review or a reproduction of source tables. Access depth is shown for each reference; an abstract-only check cannot resolve details found only in a full paper.
- WADA 2026 Prohibited List ↗Accessed 2026-11-10 · Relevant official full-text sections opened
Printed pp. 3, 9–12: introduction, S3, S4 and S5 as applicable
- NLM Stamulumab supplementary concept ↗Accessed 2026-11-10 · Relevant document text opened
Relevant cited sections
- A phase I/II trial of MYO-029 in adult subjects with muscular dystrophy ↗Accessed 2026-11-10 · Primary-study abstract on author institution record
Primary-study abstract
Check the current official WADA List and the relevant anti-doping authority for your sport, product, route and circumstances. Do not stop or change necessary treatment based on this page. Ask a qualified clinician about health decisions. Missing evidence does not establish safety.